You are here: Industry Insights > Cytocom

News List

Cytocom Receives IND for CYTO-205 Trial for COVID-19 americanpharmaceuticalreview
March 23, 2021
Cytocom announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of ...
Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy contractpharma
March 17, 2021
Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.
Cytocom submits IND application to conduct Phase II Covid-19 drug trial pharmaceutical-technology
February 19, 2021
Cytocom has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with updated protocols, to begin a Phase II clinical trial of CYTO-205 for treating Covid-19.
Cytocom and Cleveland Biolabs Merge contractpharma
October 22, 2020
Cytocom Inc. and Cleveland BioLabs Inc. have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.
Cytocom Acquires ImQuest Life Sciences contractpharma
July 21, 2020
Gains ImQuest Pharmaceuticals, BioSciences, and Life Sciences divisions, adding drug development and CRO ops, and pipeline assets.
Cytocom Announces Successful FDA Meeting for CYTO-201 Trial in COVID-19 Patients americanpharmaceuticalreview
July 07, 2020
Cytocom announced the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) in relation to the Company's planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2, the virus responsible for ...